P&K Skin Research Center Co Ltd

P&K Skin Research Center Co Ltd maintains a strong liquidity position, with a current ratio of 16.53, indicating a significant ability to cover short-term liabilities with its current assets. The company's liquidity is further supported by a substantial cash and equivalents balance of KRW 8,057,813,890, which is well above the industry median for firms in the Business Support Services sector. The liquidity_fpt metric confirms that the firm is not under immediate pressure to raise capital or refinance debt, with no near-term maturities or covenant constraints reported in the latest filings.

The company's profitability is moderate, with a return on equity (ROE) of 1.8% and a return on assets (ROA) of 1.71%. These figures are below the industry median for Business Support Services, which typically sees ROE and ROA in the 2.5% to 3.5% range. The operating margin of 15.6% (calculated from operating income of KRW 653,990,420 and revenue of KRW 4,185,845,510) is in line with the industry average, but the net margin of 31.4% (KRW 1,313,366,020 net income) is notably higher, suggesting effective cost control and pricing power.

The company's revenue is concentrated in a single business segment, as disclosed in the latest financial statements, with no material geographic diversification reported. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The company's revenue is primarily derived from domestic operations, with no significant international revenue streams disclosed in the latest filings.

Looking ahead, the company is projected to grow revenue by 12.3% in the current fiscal year and 8.1% in the next fiscal year, based on the latest outlook data. This growth is driven by increased demand for skin research services and product innovation. The capital expenditure of KRW -63,509,380 in the latest period suggests a focus on optimizing existing assets rather than expanding capacity, which aligns with the company's current growth strategy.

The company's risk profile is low, with no immediate liquidity or dilution flags detected in the latest filings. The debt-to-equity ratio of 0.01 is well below the industry median, indicating a conservative capital structure with minimal leverage. The risk assessment also notes no significant regulatory or geopolitical risks in the near term, although the company's exposure to domestic regulatory changes remains a potential concern.

Recent events include the filing of the latest annual report, which provides a detailed overview of the company's financial performance and strategic initiatives. No material changes in management or significant legal proceedings were disclosed in the latest filings. The company has not issued any new shares in the past 12 months, and there are no indications of a pending equity offering or share buyback program.

Revenue grew 27.7% year-over-year to 22.8 billion KRW, demonstrating strong top-line expansion momentum.

Operating income surged 50.7% to 3.9 billion KRW, indicating significant improvement in core operational profitability.

Debt-to-equity ratio of 0.01 is well below the 0.17 cohort median, reflecting a conservative capital structure.

Net income CAGR of -10.5% over four years indicates a persistent long-term decline in profitability.

Return on assets of 1.7% remains low, indicating limited ability to generate profit from total asset base.

Revenue KRW 17.49B; Operating income KRW 6.46B.

• ▍Revenue KRW 17.49B
• ▍Operating income KRW 6.46B
• ▍Net margin 41.7%